FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891291275> ?p ?o ?g. }

• W2891291275 abstract "e23068 Background: Analysis of cell-free circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) is a promising method for detecting and monitoring earlier stage cancers. Liquid biopsies have a large potential to detect cancer earlier upon initial recurrence and to aid in adjuvant decision making through a non-invasive and highly accurate mechanism. Methods: We developed a 30kb ctDNA capture panel based on the landscape of genomic alterations in ctDNA of over 10,000 advanced cancer patients with high theoretical clinical sensitivity for colorectal (96%) and lung (87-93%) cancers. The panel was validated with high analytical PPV (86% at MAFs < 0.025%, 96% at MAFs > 0.025%). We applied the panel to a clinical study of 63 healthy donors and also 40 early stage (II/III) CRC and lung cancer patients with both pre- and post-tumor resection blood draws. Tumor samples were also collected at the time of the surgical resection. Results: Overall, the detection rate of ctDNA in pre-op blood draws was 72% (13/18) in CRC and 67% (12/18) in lung cancer patients. In the post-op blood draws ctDNA was detectable in 11% (2/18) of CRC and 11% (2/18) of lung cancer cases. For lung cancer patients, the median MAF in pre-op was 0.06% (0.01%-8.47%, n = 51) and in post-op was 0.06% (0.02%-4.14%, n = 38). For CRC patients, the median MAF in pre-op was 0.18% (0.01%-9.26%, n = 51) and in post-op was 0.36% (0.04%-9.5%, n = 18). Sixty-three healthy donor plasma samples were screened at similar cfDNA input amounts and nine (14%) had mutations; the majority of the mutations were also detected in matched leukocyte DNA. To assess a clinically relevant biological false positive background rate in lung cancer patients, screening of cancer-free smokers is ongoing. Conclusions: We have developed a highly sensitive and specific universal assay for the detection of ctDNA in early stage CRC and lung cancer patients without the requirement of a priori knowledge of tumor mutations. This technology allows for a promising non-invasive route for molecular monitoring of residual disease post-surgery and for early detection of relapse compared to traditional methodologies." @default.
• W2891291275 created "2018-09-27" @default.
• W2891291275 creator A5005088750 @default.
• W2891291275 creator A5010311984 @default.
• W2891291275 creator A5010364211 @default.
• W2891291275 creator A5012163499 @default.
• W2891291275 creator A5014101817 @default.
• W2891291275 creator A5018920706 @default.
• W2891291275 creator A5019406140 @default.
• W2891291275 creator A5026351538 @default.
• W2891291275 creator A5063110956 @default.
• W2891291275 creator A5066161983 @default.
• W2891291275 creator A5068078797 @default.
• W2891291275 creator A5080407707 @default.
• W2891291275 creator A5090689321 @default.
• W2891291275 creator A5091197614 @default.
• W2891291275 date "2017-05-20" @default.
• W2891291275 modified "2023-09-25" @default.
• W2891291275 title "Post resection circulating residual disease monitoring in early stage lung and colorectal cancer patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity." @default.
• W2891291275 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23068" @default.
• W2891291275 hasPublicationYear "2017" @default.
• W2891291275 type Work @default.
• W2891291275 sameAs 2891291275 @default.
• W2891291275 citedByCount "0" @default.
• W2891291275 crossrefType "journal-article" @default.
• W2891291275 hasAuthorship W2891291275A5005088750 @default.
• W2891291275 hasAuthorship W2891291275A5010311984 @default.
• W2891291275 hasAuthorship W2891291275A5010364211 @default.
• W2891291275 hasAuthorship W2891291275A5012163499 @default.
• W2891291275 hasAuthorship W2891291275A5014101817 @default.
• W2891291275 hasAuthorship W2891291275A5018920706 @default.
• W2891291275 hasAuthorship W2891291275A5019406140 @default.
• W2891291275 hasAuthorship W2891291275A5026351538 @default.
• W2891291275 hasAuthorship W2891291275A5063110956 @default.
• W2891291275 hasAuthorship W2891291275A5066161983 @default.
• W2891291275 hasAuthorship W2891291275A5068078797 @default.
• W2891291275 hasAuthorship W2891291275A5080407707 @default.
• W2891291275 hasAuthorship W2891291275A5090689321 @default.
• W2891291275 hasAuthorship W2891291275A5091197614 @default.
• W2891291275 hasConcept C121608353 @default.
• W2891291275 hasConcept C126322002 @default.
• W2891291275 hasConcept C142724271 @default.
• W2891291275 hasConcept C143998085 @default.
• W2891291275 hasConcept C146357865 @default.
• W2891291275 hasConcept C151730666 @default.
• W2891291275 hasConcept C152110520 @default.
• W2891291275 hasConcept C172680121 @default.
• W2891291275 hasConcept C2776256026 @default.
• W2891291275 hasConcept C2777714996 @default.
• W2891291275 hasConcept C2778258057 @default.
• W2891291275 hasConcept C2779134260 @default.
• W2891291275 hasConcept C2779234561 @default.
• W2891291275 hasConcept C2779823535 @default.
• W2891291275 hasConcept C2780007613 @default.
• W2891291275 hasConcept C2781335228 @default.
• W2891291275 hasConcept C502942594 @default.
• W2891291275 hasConcept C526805850 @default.
• W2891291275 hasConcept C54355233 @default.
• W2891291275 hasConcept C71924100 @default.
• W2891291275 hasConcept C86803240 @default.
• W2891291275 hasConceptScore W2891291275C121608353 @default.
• W2891291275 hasConceptScore W2891291275C126322002 @default.
• W2891291275 hasConceptScore W2891291275C142724271 @default.
• W2891291275 hasConceptScore W2891291275C143998085 @default.
• W2891291275 hasConceptScore W2891291275C146357865 @default.
• W2891291275 hasConceptScore W2891291275C151730666 @default.
• W2891291275 hasConceptScore W2891291275C152110520 @default.
• W2891291275 hasConceptScore W2891291275C172680121 @default.
• W2891291275 hasConceptScore W2891291275C2776256026 @default.
• W2891291275 hasConceptScore W2891291275C2777714996 @default.
• W2891291275 hasConceptScore W2891291275C2778258057 @default.
• W2891291275 hasConceptScore W2891291275C2779134260 @default.
• W2891291275 hasConceptScore W2891291275C2779234561 @default.
• W2891291275 hasConceptScore W2891291275C2779823535 @default.
• W2891291275 hasConceptScore W2891291275C2780007613 @default.
• W2891291275 hasConceptScore W2891291275C2781335228 @default.
• W2891291275 hasConceptScore W2891291275C502942594 @default.
• W2891291275 hasConceptScore W2891291275C526805850 @default.
• W2891291275 hasConceptScore W2891291275C54355233 @default.
• W2891291275 hasConceptScore W2891291275C71924100 @default.
• W2891291275 hasConceptScore W2891291275C86803240 @default.
• W2891291275 hasLocation W28912912751 @default.
• W2891291275 hasOpenAccess W2891291275 @default.
• W2891291275 hasPrimaryLocation W28912912751 @default.
• W2891291275 hasRelatedWork W2322007103 @default.
• W2891291275 hasRelatedWork W2347160271 @default.
• W2891291275 hasRelatedWork W2522614104 @default.
• W2891291275 hasRelatedWork W2648133093 @default.
• W2891291275 hasRelatedWork W2789880866 @default.
• W2891291275 hasRelatedWork W2890380562 @default.
• W2891291275 hasRelatedWork W2891317140 @default.
• W2891291275 hasRelatedWork W2892246909 @default.
• W2891291275 hasRelatedWork W2893634359 @default.
• W2891291275 hasRelatedWork W2911945353 @default.
• W2891291275 hasRelatedWork W2938044414 @default.
• W2891291275 hasRelatedWork W2940214083 @default.
• W2891291275 hasRelatedWork W2977080314 @default.
• W2891291275 hasRelatedWork W2979359612 @default.
• W2891291275 hasRelatedWork W2994710074 @default.
• W2891291275 hasRelatedWork W3012343030 @default.

• next